Searched for
PHARMA INDEX ANALYSIS
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- 20 months of bearish markets: One additional letter that tells you which 'cheap' stocks are actually cheapMost investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...
- Nifty IT bottoming out? Anand James on the expiry outlook, pharma profit-booking, and 2 stocks to buy this weekGeojit Investments’ Anand James expects Nifty to attempt a range breakout above 23,700 during the monthly expiry week. He highlighted early...
- Stock Radar: Zydus Lifesciences stock breaks out from inverse head & shoulder pattern to hit fresh 52-week high; time to buy?Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...
- Nifty stays range-bound as resistance near 23,800 caps upside moveIndian markets ended the week with modest gains as Nifty remained range-bound, testing key resistance near 23,800 while volatility eased. T...
- F&O Talk: Weak market breadth to keep Nifty in sideways trend. Sudeep Shah's take on Amber, Tata Comm and 4 more stocksIndian markets ended higher on Friday, led by financial stocks, but analysts said Nifty remains trapped in a narrow range amid weak momentu...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsFor the next few weeks, what needs to be watched is market breadth. And also look at which sectors are leading the rally. Why? Because, at ...
- Nifty stays range bound as volatility rises; breakout awaitedNifty 50 traded within a narrow range, closing slightly higher amid rising volatility and weak momentum indicators. Markets remain in conso...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Why smallcap funds are still a buy: A long-term strategy from Aditya KhemaniSmallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...
- ETMarkets Smart Talk | Financials, industrials, healthcare top picks for FY27: Nimesh ChandanDespite geopolitical tensions and rising oil prices, Nimesh Chandan of Bajaj Finserv AMC believes India's structural economic story remains...
- F&O Talk: Midcaps, smallcaps stage sharp comeback, trade above key moving averages. What's the outlook?Domestic markets closed higher on Friday, led by consumer and metal stocks, with Nifty and Sensex posting gains. Analyst Sudeep Shah of SBI...
- BofA Securities cuts Nifty earnings target to 8.5%, says market not in value zoneBofA Securities has significantly lowered its earnings growth forecast for Nifty 50 companies to 8.5% for FY27, citing rising stagflation r...
- Dalal Street Week Ahead: All eyes on 21,700 make-or-break zone as Nifty braces for volatilityNifty ended lower after persistent selling dragged the index below key short-term supports, signalling further weakness. With the index app...
- Dalal Street Week Ahead: Avoid aggressive long positions; focus on capital preservationIndian markets experienced a significant downturn this week, with the Nifty losing over 1.28% and breaching key support levels. Volatility ...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Stock Radar: Aurobindo Pharma poised for rebound from multi-year support line; time to buy?Aurobindo Pharma stock dipped to 1,100 levels before rebounding, aligning with a channel line from October 2016’s swing high on monthly cha...
- IndusInd has 5% downside, pharma revival to continueA flat weekly close for the index doesn’t reflect the true market picture.
- 27% growth in new jobs in May 2016 (YoY), IT-Software and ITES lead the industry wise job creation: SurveyDemand for professionals in IT-Software and ITES also witnessed an upsurge in the May’16 over May’15 index.
Load More
